inc buy pt cell media revenu growth continu increas price
joint corp buy pt rel in-line result rais pt sustain profit
 strong perform new clinic analyst anthoni vendetti full summari
vivev medic inc vive buy pt weaker-than-expect reduc estim pt
cours fda approv vivev ii studi analyst anthoni vendetti full summari
inc buy pt better-than-expect revenu driven continu us growth
garrison capit inc gar buy pt nii vs dividend rel stabl reiter buy
rate price analyst michael diana full summari
time restaur inc gtim buy pt narrow loss expect solid sale shift
develop intact growth thesi analyst stephen anderson full summari
keryx biopharmaceut inc kerx buy pt auryxia grow us launch underway analyst jason
navig hold ltd nvg buy pt rein back bull expect tepid posit earn
matina biopharma hold inc mtnb buy pt cochleat deliveri could expand genom gene therapi
pluristem inc psti buy pt report quarter cell therapi advanc later stage
corpor event call maxim salesperson inform
inc atnm cover mccarthi ndr europ ceo sandesh seth princip
resapp health limit rap aux ndr nyc ceo toni keat tues-w may
genprex inc gnpx ndr nyc ceo rodney varner wed jun
annual summer confer host vendetti chokshi jang abwn bhtg
cover ndr boston cfo golder wed jun
cover hq visit orlando ceo gene cfo cardena
annual summer confer host vendetti chokshi jang abwn bhtg
corpor ctrl cover chokshi ndr boston ct nyc cfo mark novakovich tues-thur
identiv inc host chokshi group dinner nyc ceo stephen humphrey cfo sarah wallach
annual silicon valley bu tour host chokshi tue juli
annual summer confer host vendetti chokshi jang abwn bhtg
navig hold ltd nvg cover jang group luncheon nyc ceo david butter tue may
annual summer confer host vendetti chokshi jang abwn bhtg
biolif report biopreserv media revenu
sequenti y/i margin also continu rise increas volum
come compani cash flow posit current
cash balanc sheet includ warrant exercis
recent biolif valuat continu rise media revenu grow
compani becom deepli integr evolv cell therapi
space increas outyear estim cell media revenu
increas price target
compani reiter revenu guidanc increas
expect margin oper expens expect
three custom product track regulatori file posit
approv commerci custom indic
disclos rememb commerci product repres
recur revenu regen medicin space
includ car-t
conclus biolif cell media continu integr cell therapi
space becom embed develop process clinic
commerci cell therapi advanc later stage develop
biolif posit beneficiari see biolif tangenti
play cell therapi space
biolif current suppli custom biolif custom
move close market exampl kolon life scienc
nr receiv approv knee osteoarthr korea kite pharma acquir
gilead buy approv yescarta came octob car-t repres
signific growth across multipl vertic biolif media logist expertis
shipper repres best industri commerci product
repres annual revenu compani
right media cell storag ship cell therapi space continu
grow exponenti passag centuri cure act paradigm
shift car-t part drive billion new industri biolif
biopreserv media cold chain logist platform play critic role cell
therapi provid right media store cell ship
perfect condit get efficaci viabl product patient stabil
shelf-lif function recoveri cell use cell therapi paramount
deliv efficaci product cell may need maintain normotherm
bodi temperatur hypotherm cool frozen temperatur differ condit
requir special media maintain cell viabil recoveri biolif two lead
media product hypothermosol fr cool cryostor freez minim cell
tissu swell reduc damag free radic keep ion concentr
right low temperatur provid high energi food cell use stimul
recoveri warm back avoid acid damag inhibit apoptosi
necrosi net result cell product viabl maintain
click full note
better-than-expect revenu driven continu
us growth reiter buy
revenu y/i well estim
consensu domest revenu grew y/i
compani launch bcaa recoveri drink line extens europ
expand distribut locat china
gaap ep slightli narrow estim
in-line consensu
april announc appoint john fieldli
introduc estim revenu ep
bottom line would continu buyer report better-than-
expect result remain optimist compani expand distribut
channel new product launch intern rollout specif compani
continu see strength multipl channel us record
revenu total revenu expans asia believ roll-out
asia still earli inning encourag region quickli
becom signific contributor compani overal believ celsiu remain
well posit capit global health well trend compani
continu invest behind brand product
perman ceo april announc appoint john fieldli
perman ceo interim-cfo mr fieldli serv cfo compani
sinc januari addit interim-ceo sinc march view
promot perman ceo posit given six-year tenur
compani recent accomplish includ success launch heat
natur product line extens well brand entri asia compani
activ search new perman cfo
result summari yesterday market close report
revenu y/i well estim
consensu domest revenu y/i intern
revenu y/i domest growth driven continu strong
double-digit growth channel trade growth mainli driven
launch bcaa recoveri drink line extens europ expand
distribut locat china gross margin y/i
slightli estim consensu ep
slightli narrow estim in-line consensu
march cash equival
revis estim due better-than-expect revenu
increas revenu estim leav
revenu estim unchang howev due expect higher expens
reduc ep estim
respect
compel valuat share current trade ev/revenu estim
compar peer averag price target base dcf
analysi discount rate termin growth rate impli share
trade ev/revenu estim premium peer believ
justifi due differenti product above-p revenu growth us
signific intern expans opportun east asia
click full note
rel in-line result rais pt
sustain profit strong perform new
revenu y/i rel in-line
estim consensu
system-wid comp sale grew y/i includ y/i growth matur
clinic open month
adjust ebitda compar slightli
estim consensu
gaap ep slightli wider estim consensu
compani open seven franchis clinic quarter total
also end corporate-own clinic flat sequenti
announc addit one buy-back april
introduc estim revenu ep
bottom line would continu buyer announc rel
in-line result reiter guidanc compani report posit
adjust ebitda third consecut quarter resum expans
corporate-own clinic portfolio first buy-back complet april
expect continu expand brand hybrid model corporate-
own franchis clinic believ clinic rapidli add valu given
improv perform franchis clinic open compani
overal remain optimist compani growth potenti top retail
chain highli fragment rapidli grow chiropract market
result summari yesterday market close report
revenu y/i rel in-line estim
consensu system-wid comp sale grew y/i gross margin
y/i estim slightli consensu
adjust ebitda compar slightli
estim consensu ep
slightli wider estim consensu march
compani cash equival outstand debt
avail line credit
rais estim due expect strong perform newli open
clinic slightli rais revenu estim
respect result increas revenu
partial off-set higher expect payrol expens increas
ep estim respect
attract valuat current trade ev/revenu estim
compar peer averag due higher estim increas
price target new price target base dcf
analysi discount rate termin growth rate impli share
trade ev/revenu estim industri averag
forecast signific growth highli fragment chiropract market
click full note
cours fda approv
revenu y/i significantli estim
consensu compani sold system
treatment tip quarter
gaap ep compar wider
estim consensu
march vive receiv fda approv investig devic
exempt conduct vivev ii studi posit step increas
yesterday compani announc appoint scott durbin ceo
mr durbin previous serv cfo replac patricia scheller
introduc revenu estim revenu
gaap ep
bottom line would continu buyer vive despit report weaker-than-
expect result compani progress vivev ii stress
urinari incontin clinic studi opinion expand fda approv
improv femal sexual function expans market
repres compani largest growth opportun moreov encourag
compani acceler invest behind north american sale team
sold system region bring vive global instal base total system
intern asia pacif continu compani second largest sale region
see strong physician respons hybrid direct distributor sale model
europ overal believ vive remain track global commerci
strategi continu adopt genevev system well posit
leader women health
result summari yesterday market close vive report
revenu y/i significantli estim
consensu genevev system ship includ north
america bring total commerci instal base system vive also sold
approxim consum treatment tip quarter gross margin
y/i significantli estim consensu
primarili due chang mix product sold quarter
slightli lower promot program ep compar
wider estim consensu
march vive cash equival
outstand debt
revis estim due result expect lower
revenu estim
result expect higher expens widen
gaap ep estim respect
compel valuat share current trade ev/revenu estim
compar peer averag new price target base
dcf analysi discount rate termin growth rate impli share
trade ev/revenu estim believ justifi due
compani defens technolog posit signific growth potenti
click full note
narrow loss expect solid sale
shift develop intact
maintain buy rate price target time restaur
gtim follow releas full march result yesterday
gtim deliv narrow pro forma loss expect thank solid sale
time sale strong new unit perform bad daddi
sale new shift develop lower-cost region
rais comp estim time
strength recent menu initi though lower comp estim bad
daddi account temporari unit closur
cannib coupl market
gtim shift bad daddi open though believ
new unit pipelin remain strong meanwhil expect manag
restart select new unit growth time follow closur
older lower-margin locat
growth thesi remain intact compani believ gtim
ep loss per share pro forma actual vs loss maxim
revenu actual vs maxim street three analyst
comp time bad daddi alreadi report april
adjust ebitda ratio actual vs maxim
adjust ebitda tighten high end guidanc vs
maxim pre-releas prior guidanc revis estim
time rais vs maxim pre-releas prior guidanc
revis estim
bad daddi lower posit vs maxim pre-releas
prior guidanc revis estim
growth thesi remain intact compani believ gtim
compel valuat unchang price target gtim reflect primarili
outlook rapid expans bad daddi along gradual comp
rebound time gtim yet gener net incom valuat
methodolog base ebitda gener concept use
base valuat year determin fair valu gtim base combin
valuat model use ebitda multipl time ebitda
multipl bad daddi arriv unchang price target
click full note
rein back bull expect tepid posit
follow manag expect tepid earn lower
estim expect nvg maintain profit
nvg report net revenu million ebitda million
net incom million ep
lower ep estim expect
delay marin east pipelin construct well forc majeur
declar marin east pipelin impact earn
look oper ep prior reduc spot rate
forecast non-ethylen capabl carrier
although lower estim remain bullish nvg
compani signific oper leverag increas export
market certain export project move ahead expect nvg acquir
long-term charter mid-cycl rate
result mix increas cost pull bottom line
yesterday post-clos nvg report slight beat top line report net
revenu million versu estim million profit
ep howev million increas oper cost per share
led miss bottom line
manag believ near-term earn could challeng
adjust estim accordingli call today manag commun
challeng rate environ carrier sector therefor base
conserv view market readjust oper expens model
lower estim look net revenu million
unchang ebitda million million prior oper ep
ep prior expect net revenu million
million prior ebitda million million prior oper ep
ep prior
near-term could challeng export project could help nvg achiev
mid-cycl rate beyond forecast period due sinkhol discov near
marin east pipelin export disrupt mid-may like
neg effect rate howev marin east pipelin near
complet complet oper
open addit bpd export marcu termin
handys carrier look beyond forecast period ethylen export
termin jointli develop nvg enterpris product partner epd nr
schedul possibl ethylen export start earli
ehtylen remain driver nvg global demand ethylen remain strong
spread global ethylen
believ ethylen export project could prioriti near term factor
all-in transport cost arbitrag opportun intern
ethylen import remain strong
bottom line although expect headwind sector
sector work supply/demand constraint maintain long-term thesi
nvg deliv outsiz earn export project come on-line
therefor maintain buy rate price target price target
base multipl prior forward normal
prior believ premium multipl warrant nvg
signific oper leverag rise market
click full note
report quarter cell therapi advanc later
pluristem report quarter fye june spend oper
expens end period cash compani also receiv
non-dilut fund grant sourc support
cell therapi program estim compani fund well
multipl program continu advanc late stage develop plx-pad
cell highlight detail
recent plx-pad cell clear move hip fractur
recoveri build muscl mass support heal recoveri
cell also grant ind clearanc emerg use treat high radiat
exposur attack accid base prior studi non-human
primat posit safeti data human
conclus pluristem continu advanc allogen shelf
cell cell therapi plx-pad later stage develop
compani cash balanc sheet signific sourc non-
dilut capit runway well multipl catalyst
associ on-going clinic program
plx-pad critic limb ischemia pluristem launch phase studi
patient us eu primari endpoint- time event amput
death measur efficaci includ af qualiti life pain score
dose regimen two dose million cell two month apart placebo
discuss statist trial length voic
concern trial power assumpt manag believ month
follow-up increas studi power allow smaller trial japan
compani previous enter joint ventur newco sosei cvc
nr pluristem own newco carri pivot trial japan
pivot trial clear initi muscl recoveri follow femor
neck fractur surgeri studi expect enrol patient
random receiv intramuscular inject plx-pad cell
placebo end point studi chang short physic perform batteri
sppb week prior studi muscl volum improv
chang muscl forc improv
program report posit result phase ii-equival studi non-
human primat compani discuss fda sever
 government agenc clear path pivot studi model
commerci direct sale us gov june ye pivot
data expect later year trial expect move quickli
oper fda anim rule addit studi univers
indiana examin addit popul geriatr pediatr well
interact drug data year use support bla
insuffici hct recoveri hct program current phase
trial insuffici hematopoiet cell transplant recoveri data expect
later year compani eu patent cover potenti indic relat
bone marrow inabl produc cell autoimmun diseas genet
disord etc model commerci direct sale
click full note
cochleat deliveri could expand genom gene
matina report net loss end period
cash publish previous expect matina rais capit
dilut alreadi factor model compani addit
develop fungal infect aim expand cochleat
deliveri platform genom rnai partner come board could
bring non-dilut capit form up-front payment
cochleat bring gt ge rnai table- cochleat solid
lipid nanocryst made phospholipid calcium
natur immunogen use viral vector ge gt present
challeng immunogen alreadi seen space rnai
deliveri also difficult term target leaki liposom cochleat
solid leak-proof alreadi shown in-vitro in-vivo deliveri
partner want may come board soon- gt ge rnai
space activ seen rise valuat matina
cochleat view could attract partner space aim
diversifi approach nucleic acid deliveri potenti overcom
challeng current avail deliveri vehicl virus liposom
lead program amphotericin cochleat move
closer adapt design trial prophylaxi prevent ifi invas
fungal infect blood cancer patient trial could potenti support
registr updat expect design final expect initi
conclus advanc want begin shift investor
attent toward view cochleat drug deliveri platform expect
potenti util nucleic acid deliveri could attract partner diversifi
pipelin bring non-dilut capit
path forward matina met fda discuss safeti
overst amphotericin see efficaci mucos infect
recal goal indic prophylaxi prevent invas fungal
infect ifi initi acut lymphoblast leukemia adapt design trial
all/aml plan could serv pivot studi given unmet need
anti-fung use studi two stage stage one
evalu dose safeti follow stage two efficaci
beyond anti-microbi cochleat extend multipl molecul includ dna
rna protein matina target collabor announc
repres catalyst stock addit could sourc non-
dilut capit form up-front payment also expect data present
confer optim data provid
click full note
auryxia grow us launch underway
keryx report total revenu net loss
auryxia us sale quarter prior quarter
compani report cash balanc sheet keryx also
refinanc convert note leverag grow asset base
revolv line credit
prescript volum continu grow auryxia rx volum increas
y/i owe addit prescrib
increas prescript volum per prescrib vs compar quarter
importantli view auryxia also continu grow q/q
binder market remain flat expect trend could continu base
monthli april rx number repres increas
averag monthli rx count
pill per script suggest label expans iron defici anemia
gain traction bring addit new patient elig
auryxia still earli launch specif breakdown revenu
disclos yet averag tablet per rx drop requir
fewer pill patient dialysi suggest new script
written
conclus auryxia revenu continu grow awar build
among nephrologist keryx sale forc sampl program
expect trend continu trajectori start steepen
launch continu gain traction
big pictur product uptak slow posit label chang
combin feedback physician nephrologist dialysi provid
suggest time auryxia grow believ sale forc new data
american societi nephrolog stronger posit make doctor
call combin sampl program keryx market strategi
alreadi yield result doctor receiv sampl wrote
prescript previous cite multipl peer-review journal articl
valid opinion auryxia better phosphat binder iron-
spare epogen-spar qualiti view win patient provid
payer
defici anemia adult chronic kidney diseas label chang
addit indic includ patient dialysi open new market
compani keryx press releas site one everi seven adult
 chronic kidney diseas keryx estim nephrologist current
treat peopl chronic kidney diseas dialysi
estim addit peopl care
nephrologist chronic kidney diseas treat today
preval sever increas kidney diseas progress
click full note
nii vs dividend rel
stabl reiter buy rate price target
gar report ep versu dividend
rel stabl
maintain dividend estim repres yield
 cover earn remain three quarter
gar resolv legaci problem loan
valu closer peer encount difficulti price
target equat modest discount
level believ well-perform bdc trade current
incom nii per share aid incent fee offset versu
dividend per share ep due loss new non-
accrual loan net asset valu rel stabl
dividend exceed ep
credit qualiti gar final resolv problem loan
hinder perform driven lower
one last legaci problem loan energi sector remov
non-accru one new non-accru equal invest
fair valu gar non-accru loan
data gar yield invest portfolio versu
strong origin match elev payoff result almost
chang size invest portfolio
leverag similar-s invest portfolio slightli less equiti total leverag
increas slightli equiti statutory/regulatori leverag without
sba debentur stabl equiti versu current statutory/
regulatori leverag limit note accord recent legisl
gar board director approv increas statutory/regulatori leverag
limit equiti take effect march gar
still capac make new loan transitori asset could sold
maintain dividend estim expect dividend
cover earn remain three quarter manag express
confid cover dividend aid incent fee offset least
time dividend level could revisit factor could possibl
help gar nii dividend coverag includ fed rate hike
nii increas everi increas libor refinanc
clo nii increas increas statutory/regulatori
leverag limit equiti discuss page updat
maintain price target price target equat
modest discount level believ well-perform bdc
trade current environ gar resolv legaci problem
loan valu closer peer encount difficulti
reiter buy rate next four quarter expect dividend
yield stock price appreci price target
result estim total return
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
receiv full disclosur compani maxim group coverag mention report pleas send
